- Home
- AMAL vs TNGX Comparison
AMAL vs TNGX Comparison
Compare AMAL & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMAL
- TNGX
- Stock Information
- Founded
- AMAL 1923
- TNGX 2014
- Country
- AMAL United States
- TNGX United States
- Employees
- AMAL N/A
- TNGX N/A
- Industry
- AMAL Commercial Banks
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- AMAL Finance
- TNGX Health Care
- Exchange
- AMAL Nasdaq
- TNGX Nasdaq
- Market Cap
- AMAL 858.7M
- TNGX 723.2M
- IPO Year
- AMAL 2018
- TNGX N/A
- Fundamental
- Price
- AMAL $27.58
- TNGX $7.35
- Analyst Decision
- AMAL Hold
- TNGX Strong Buy
- Analyst Count
- AMAL 2
- TNGX 6
- Target Price
- AMAL $33.00
- TNGX $10.00
- AVG Volume (30 Days)
- AMAL 149.9K
- TNGX 1.5M
- Earning Date
- AMAL 10-23-2025
- TNGX 11-05-2025
- Dividend Yield
- AMAL 1.99%
- TNGX N/A
- EPS Growth
- AMAL 3.73
- TNGX N/A
- EPS
- AMAL 3.34
- TNGX N/A
- Revenue
- AMAL $304,724,000.00
- TNGX $24,296,000.00
- Revenue This Year
- AMAL $9.82
- TNGX $20.42
- Revenue Next Year
- AMAL $11.11
- TNGX N/A
- P/E Ratio
- AMAL $8.44
- TNGX N/A
- Revenue Growth
- AMAL 4.35
- TNGX N/A
- 52 Week Low
- AMAL $25.03
- TNGX $1.03
- 52 Week High
- AMAL $38.19
- TNGX $10.81
- Technical
- Relative Strength Index (RSI)
- AMAL 36.51
- TNGX 60.63
- Support Level
- AMAL $28.32
- TNGX $6.38
- Resistance Level
- AMAL $29.19
- TNGX $6.90
- Average True Range (ATR)
- AMAL 0.60
- TNGX 0.44
- MACD
- AMAL -0.06
- TNGX 0.00
- Stochastic Oscillator
- AMAL 6.07
- TNGX 94.14
About AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management and trust and custody services.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.